About Conifer Point
Conifer Point is a Healthcare company based in Doylestown (United States) founded in 2015, and was acquired by Lodo Therapeutics in August 2020. New drugs are developed using custom fragment-based design software. Conifer Point offers products and services including Boltzmann Maps and Computational Chemistry Services. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In SIlico Assays. Its competitors include Cellumen, PointCross and IOTA Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Developer of new drugs using custom fragment-based drug design software. Services offered include molecular dynamics simulations, quantum mechanical simulations, hot-spot mapping, and water mapping. The pipeline includes renin and DHFR in a hit to lead stage for hypertension and gram-negative bacteria, d-ala-d-ala ligase for tuberculosis and gram-negative bacteria in the hit validation stage, and PD-1 for immuno-oncology in the computational chemistry stage
- Headquarters Doylestown, United States
- Stage Acquired
- SectorsHealthcare
- Website coniferpoint.com
- Acquired by Lodo Therapeutics (Aug 2020)
- Latest Funding Round$2.94M (USD), Grant
Jul 2020
- InvestorsHHS
& 1 more
- Acquired byLodo Therapeutics
(Aug 2020)
Products & Services of Conifer Point
Conifer Point offers a comprehensive portfolio of products and services, including Boltzmann Maps and Computational Chemistry Services.
Web application for designing and prioritizing small molecules in pre-clinical drug discovery.
Services to design, improve, and screen compounds for targeted drug research applications.
Funding Insights of Conifer Point
- Total Rounds 2
- Last Round Grant — $2.94M
- First Round $1.81M
(Jun 2016)
- Investors Count 1
All 2 funding rounds of Conifer Point with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Conifer Point
Conifer Point has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lodo Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | 2015 | lodotherapeutics.com | New York, United States |
Investor details for Conifer Point
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Conifer Point
4 dated milestones of Conifer Point across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Conifer Point is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Grant, of $2.9M.
- Exit Acquired by Lodo Therapeutics.
Competitors of Conifer Point
Conifer Point has 3 listed competitors in our database, 2 of them funded. They include Cellumen, PointCross and IOTA Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellumen.com | 2004 | Pittsburgh, United States | $11.43M | Systems biology solutions for drug safety and efficacy are provided. | ||
| pointcrosslifesciences.com | 2000 | Foster, United States | $120,000 | Big data platform & desktop software for preclinical & clinical research & regulatory applications | ||
| iotapharma.com | 2007 | Cambridge, United States | Offers fragment-based drug discovery products and services. |
Detailed competitors of Conifer Point
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Conifer Point (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Conifer Point
Complete news archive for Conifer Point
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Conifer Point
Conifer Point was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Conifer Point is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Developer of new drugs using custom fragment-based drug design software. Services offered include molecular dynamics simulations, quantum mechanical simulations, hot-spot mapping, and water mapping. The pipeline includes renin and DHFR in a hit to lead stage for hypertension and gram-negative bacteria, d-ala-d-ala ligase for tuberculosis and gram-negative bacteria in the hit validation stage, and PD-1 for immuno-oncology in the computational chemistry stage.
Conifer Point's top competitors include Cellumen, PointCross and IOTA Pharma.
Conifer Point offers Boltzmann Maps and Computational Chemistry Services.
Conifer Point has 2 investors. Key investors include HHS, and Lodo Therapeutics.
Yes. Conifer Point was acquired by Lodo Therapeutics in August 2020.